|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
|
25384085 |
2014 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, RET, and HER2 have been under development.
|
27686809 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET fusion gene: translation to personalized lung cancer therapy.
|
23991695 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
|
28082048 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrated that this novel polymorphism of the RET gene is associated with an increased risk of lung cancer in the Korean population.
|
20944145 |
2010 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.
|
22194472 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that RET chromosomal rearrangement may represent a genetic mechanism of radiation-induced lung cancer.
|
24346100 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is anticipated this agent will be an effective targeted therapeutic option for patients with RET positive lung cancer.
|
31058838 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As overlapping gene fusions involving actionable kinases are emerging in both IMT and lung cancer, we set out to evaluate abnormalities in ALK, ROS1, PDGFRB, NTRK1, and RET by fluorescence in situ hybridization.
|
25723109 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.
|
23856031 |
2013 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Gain of copy number and amplification of the RET gene in lung cancer.
|
25303898 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations in the tyrosine kinase enzyme RET are found in thyroid and lung cancer.
|
29908090 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
|
24418728 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that heterodimers of MET with EGFR, HER2, HER3, or RET have differential roles in tumour development, and they provide new insight into the function of trans-phosphorylated RTKs as heterodimerisation partners of MET in lung cancer with MET amplification.
|
21847121 |
2011 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Investigators in the LIBRETTO-001 phase I/II trial presented new data on the experimental RET inhibitor selpercatinib at the 2019 World Conference on Lung Cancer.
|
31554640 |
2019 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction to: KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.
|
31739795 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the first bench-to-bedside evidence that RET inhibitor combined with an mTOR inhibitor is active against brain-metastatic RET-rearranged lung cancer and the first evidence of blood-brain barrier penetration.
|
25982012 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved.
|
29912274 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
|
22327622 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The accrual of patients with RET-rearranged lung cancer to this protocol has been completed but the trial is still ongoing because several patients remain on active treatment.
|
27825636 |
2016 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To verify the oncogenic activity of KIF5B-RET kinase in lung cancer cells, we manipulated its expression genetically followed by colony formation and tumor formation assays.
|
25047660 |
2014 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied.
|
23154560 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The KIF5B-RET fusion defines an additional subset of lung cancer with a potentially targetable driver oncogene enriched in never smokers with "pan-negative" lung adenocarcinomas.
|
23052255 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
|
29885946 |
2018 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The RET/β actin mRNA levels were not significantly different between lung cancer (6.359 ± 15.268) and adjacent normal lung tissues (8.205 ± 28.931, P = 0.6332).
|
23342255 |
2012 |